LIFE MEDICAL SCIENCES REPORTS POSITIVE INTERIM ANALYSIS RESULTS FROM REPEL-CV PIVOTAL CLINICAL TRIAL

Life Medical Sciences has announced that a planned interim analysis of patient data from its REPEL-CV pivotal clinical trial was completed by a data and safety monitoring board (DSMB) comprised of medical and biostatistical specialists who are not participating in this clinical trial. Based on data from more than 40 patients, the DSMB recommended that the trial proceed as planned and that no modifications to the trial protocol were indicated. To preserve the integrity of the clinical trial, the company remains blinded to the data.

Yahoo News (http://biz.yahoo.com/prnews/050105/nyw171_1.html)